Pasithea Therapeutics - Warrants (11/08/2026) Return on Equity

The latest ROE for KTTAW is -63.4%. That is above the Healthcare sector average of -75.84%. Investors often review this figure alongside Pasithea Therapeutics - Warrants (11/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, KTTAW currently prints -63.4% for ROE, while the sector average sits near -75.84%. That is roughly 16.4% above the sector mean. Large gaps often invite a closer look at Pasithea Therapeutics - Warrants (11/08/2026)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Pasithea Therapeutics - Warrants (11/08/2026) converts resources into returns. At -63.4%, KTTAW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting KTTAW's ROE (-63.4%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Pasithea Therapeutics - Warrants (11/08/2026)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.